Increasing uptake of colon cancer screening in a medically underserved population with the addition of blood-based testing

Stephanie Ioannou (✉ stephanie.ioannou@jhsmiiami.org)
University of Miami Health System  https://orcid.org/0000-0001-9097-9192

Kyle Sutherland
University of Miami Health System

Daniel A. Sussman
University of Miami Health System

Amar R. Deshpande
University of Miami Health System

Research article

Keywords: colorectal cancer, screening, non-invasive, medically underserved, health fair

Posted Date: October 5th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-75393/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License

Version of Record: A version of this preprint was published at Gastroenterology on May 1st, 2019. See the published version at https://doi.org/10.1016/S0016-5085(19)38405-7.
Abstract

Adherence to colorectal cancer screening is suboptimal, particularly in medically underserved populations. We report here on our assessment of the impact of offering a blood-based screening test on screening rates in a health fair setting. Patients attending student-run health fairs who met colon cancer screening guideline eligibility criteria received a recommendation to attend that screening station. Patients were offered recommended accepted screening methods, and if they declined they were offered blood-based testing. Screening rates, test outcomes, and the rate of follow up completion of colonoscopy were measured and compared with historic screening outcomes. Of 1401 screening eligible patients, 640 (45.7%) attended the colon cancer screening station, of whom 460 were eligible for assessment. Amongst these, none selected colonoscopy, 30 (6.5%) selected FIT, and 430 (93.5%) selected blood-based testing. Only 2 patients returned the FIT. For the blood test, 88 were positive, and 20 of these received a follow up colonoscopy. Based on this assessment, blood-based testing is an effective method to increase screening rates in medically underserved populations, though efforts to further improve access to follow up colonoscopy are necessary.

Background

Colorectal cancer (CRC) is the second leading cause of cancer mortality nationally. Routine screening for CRC, such as with colonoscopy and fecal immunochemical testing (FIT), at regular intervals leads to earlier CRC detection, lower CRC incidence and mortality, and overall cost savings compared to no screening. However, there are significant barriers to screening within medically underserved populations (MUP), due in part to cost, accessibility, and acceptability of screening tests. Behavioral Risk Factor Surveillance System (BRFSS) survey data identified low CRC screening rates among patients without healthcare coverage (37%) compared to those with health insurance (69%), as well as lower rates in patients who lack an identifiable healthcare provider (31%) compared to those with a regular provider (69%). Low income and lack of insurance lead to later CRC detection, worse outcomes, and increased mortality from CRC.

To date, there are many well-established CRC screening modalities, which can be divided into invasive (capsule endoscopy, sigmoidoscopy, or colonoscopy) or non-invasive testing options (computed tomographic colonography and stool-based testing), and can be further categorized into those detecting polyps versus cancers. In the United States, the most utilized method for CRC screening is colonoscopy, but it is not necessarily an ideal screening tool in MUP given its cost, invasiveness, risk, lack of convenience and accessibility, and patient perception. To that end, the other modalities remain important alternative screening options. In fact, modeling studies clearly demonstrate that all of the screening methods have benefit over time, and that adherence to testing, regardless of modality, is a key driver for successful screening. Many people are not up-to-date with CRC screening despite the available testing, with overall screening rates under 70% in the United States in 2018.
characteristics of a MUP, such as low income, lack of insurance or being underinsured, and lack of a PCP, make screening an even bigger challenge for this group.

FIT has desirable characteristics for the MUP including cost, availability, and efficacy. It has been used frequently for CRC screening in this population, and programmatic FIT has been shown to be effective\textsuperscript{12}. However, return rates are consistently low, around 10%, in MUP compared to the general population\textsuperscript{13}. For MUP without access to a primary care provider who may use health fairs as their principal source of health care, low FIT return rates limit the feasibility of this option.

The Mitchell Wolfson Sr. Department of Community Service (DOCS) is a medical student-run, organization at the University of Miami Miller School of Medicine that provides preventive, primary, and subspecialty care to thousands of MUP in South Florida through various organized activities, including free comprehensive screening health fairs. This patient population is almost exclusively uninsured or underinsured, and a large percentage are not eligible for state or federal programs that facilitate primary care. The county safety net health system affords care for some, but this is mostly in the emergent or urgent settings rather than for elective issues like cancer screening. Therefore, the lone modality of colorectal cancer screening at these fairs has been fecal occult blood testing for many years, initially with guaiac-based and, then, with immune-based testing (FIT), given its affordability. However, we had noted consistently low return and positivity rates of FIT at our health fairs, in line with known national averages\textsuperscript{13}. In the year prior to the data collection presented here, when FIT was the primary CRC screening option offered, 414 patients received FIT but only 52 returned them (12.6%) with 0 being positive (0%).

Blood-based testing presents an opportunity to overcome some, but not all, of the barriers that currently limit screening, particularly in MUP, including ease of use and educational barriers to test use and return. The FDA-approved Septin9 DNA blood test (Epi proColon\textsuperscript{®}) is indicated for screening of patients unwilling or unable to undergo the other recommended tests. This test determines the methylation status of the SEPT9 gene, a member of the Septin family of proteins that bind GTP and act to modulate vesicle trafficking, apoptosis, cytoskeletal remodeling, and cytokinesis\textsuperscript{14}. Hypermethylation of the SEPT9 gene in CRC tissue is associated with colorectal carcinogenesis\textsuperscript{15} and methylated SEPT9 DNA (mSEPT9) shed from the tumor site is measurable in peripheral blood, providing a blood-based means to test for CRC\textsuperscript{16,17}. Several studies have compared mSEPT9 and FIT testing, and test sensitivity has been found to be comparable across all stages, though at lower mSEPT9 specificity. In one prospective multi-center study, mSEPT9 sensitivity was 73% at a specificity of 80%, compared to 68% at 97% for FIT\textsuperscript{18}.

Given the potential for a blood-based test to improve screening rates for MUP, we developed a program to assess the impact of adding mSEPT9 testing to our CRC screening station at the DOCS health fairs. Here we report on CRC screening uptake with both mSEPT9 and FIT in MUP and secondarily the performance characteristics of the blood-based test in this resource-limited and ethnically diverse environment.

**Methods**
The CRC screening assessment received approval from the Institutional Review Board at the University of Miami. All patients recruited at the DOCS health fairs provided consent upon check in at the fair. A retrospective chart review was performed of all patients attending DOCS health fairs from April 2017 to April 2019. In 2016, DOCS data collection was transitioned from paper charts to an electronic medical record system using REDCap, a secure metadata-driven Electronic Data Capture (EDC) software and workflow methodology for designing clinical and translational research databases while ensuring HIPAA compliance\(^\text{19}\). All patients over age 50 years attending DOCS health fairs in South Florida during the predetermined two-year period were asked to visit the CRC screening station during their time at the fair.

At the CRC screening station, those who were at average risk of colorectal cancer (defined as age 50–75 without rectal bleeding or previous history of colorectal polyps, CRC, inflammatory bowel disease, familial cancer syndromes, or family history of CRC) and not up-to-date with CRC screening (no colonoscopy within the last 10 years, sigmoidoscopy within the last 5 years, or FIT within the last 1 year) were educated on CRC screening by station volunteers using a prewritten script that also explained their options for screening (see Appendix 1). Translators were used if English was not the patient's primary language of preference.

A screening questionnaire was administered at the CRC station, and a prewritten script was used with the goal of providing an objective, unbiased approach to CRC screening options. Patients were offered the option of assistance in getting a screening colonoscopy within the county safety net hospital system, however given lack of access to the healthcare system for the majority of patients, a script was used to explain that colonoscopy could not be guaranteed. Patients were also offered the option of a take-home FIT screening kit at the fair in the patient's primary language to be completed as per kit instructions and mailed back to DOCS in the provided prepaid addressed return envelope. In line with the intended use of the blood test, patients were offered and declined both colonoscopy and FIT before being offered blood-based mSEPT9 testing. Screening modalities were offered in a stepwise fashion in accordance with current guidelines for CRC screening, with gold standard being colonoscopy and FIT having increased sensitivity, affordability, and familiarity.

On acceptance of mSEPT9 testing, a blood sample was collected by venipuncture-trained student volunteers and processed on-site per manufacturer instructions for use. Plasma was stored and shipped in labeled 5-mL screw-cap and flat-bottom transport tubes at -15 °C to -25 °C to Molecular Pathology Laboratory Network, Inc (MPLN) (Maryville, TN) for testing. Results were reported online in MPLN's LIS Blue laboratory management system 1–2 weeks after the health fair. FIT kits were instructed to be returned by mail to the University of Miami and were processed at the University of Miami laboratory.

All patients who elected for the mSEPT9 blood draw or mail-returned a FIT kit had their results mailed to them in their primary language, including an explanation of appropriate follow-up recommendations, within 2–4 weeks of sample collection or return of FIT kit. Patients who screened positive for either test were contacted by telephone 2, 4, and 6 weeks after receiving their results by trained medical student patient navigators to assist in facilitating follow-up colonoscopies; patients were followed until time of
colonoscopy completion or for up to nine months after sample collection, whichever came first. Screening rates, test rate positivity, and follow-up colonoscopy rates for both FIT and mSEPT9 were analyzed.

**Results**

A total of 2,513 patients attended 19 health fairs from April 2017 to April 2019. Of all health fair attendants, 1,401 (55.8%) patients were over 50 years old and directed on initial intake to the CRC screening station. Of those directed to the CRC screening station, 640 patients attended the CRC screening station (45.7%). At that station, 159 patients were excluded for being greater than average risk (42) or being up-to-date with screening (117). Of the 481 remaining eligible patients, 21 patients had incomplete medical records. Therefore, 460 patients were included for retrospective analysis. Of these, 50% were uninsured and 47% had not seen a PCP within the preceding year. No patient chose to pursue colonoscopy as the initial screening test. Thirty patients (6.5%) chose to pursue FIT, and 430 (93.5%) patients elected for mSEPT9 testing (Table 1).

Two of the 30 patients who chose FIT returned the test (6.7%) and neither was positive (0%). Of the 430 patients who had blood-based testing, 88 (20.5%) screened positive. In the nine-month follow-up period, 20 (22.7%) of the 88 patients who screened positive received diagnostic colonoscopies, 48 (54.5%) were pending colonoscopies due to financial constraints, and 20 (22.7%) were considered lost to follow up after three failed attempts to contact. In those who received diagnostic colonoscopies to date, no high-risk lesions (adenomas > 1 cm, villous features, high-grade dysplasia, serrated lesions, or cancers) have been identified.

**Conclusion**

The availability of mSEPT9 screening in MUP unwilling or unable to complete FIT or colonoscopy led to a marked increase in screening uptake when compared to years prior, where FIT was the only screening modality offered at the health fairs. For eligible patients, the rate of testing increased from 12.6% completing testing with FIT the previous year to 93.5% with the blood test. Although navigation to colonoscopy was offered, it was not a comparator in the study as we had no prior data, and in our health-fair setting, most patients are uninsured or underinsured, and thus experience great difficulty accessing colonoscopy. The introduction of a novel approach to CRC screening (blood-based testing) when compared to FIT has proven to be well-received by our MUP, likely as a result of convenience and ease of testing. In this study, we demonstrate that tests performed same-day at health fairs are likely to have higher uptake than those tests that are less accessible to these populations. In the health fair setting, patients have been accustomed to providing blood samples for other screening tests, and it is likely that the execution of blood-based CRC testing is more in line with a patients’ expectations of medical care than is sample acquisition for stool-based testing. It is probable that the inconvenience posed by completing and returning a FIT also plays a role in patient preference.
These findings are in line with previous studies on blood-based testing. In a cross-sectional survey of 100 participants, blood-based testing was ranked as a first or second choice of screening in 91% when compared with colonoscopy, sigmoidoscopy, or stool testing. Participants preferred mSEPT9 over FIT and/or colonoscopy due to convenience (60%), low cost (47%), low level of discomfort (30%), lack of required bowel preparation (28%), and more frequent screening intervals (18%)\(^{20}\). Further data will be needed in order to better understand patient choice in the health fair setting when selecting among CRC screening tests.

The mSEPT9 blood test had similar characteristics as previously reported in studies where patients had access to care; however, the number of patients requiring diagnostic colonoscopy for positive mSEPT9 is worthy of consideration. Despite patient agreement to participate in accessible screening modalities, barriers to further care pose additional complications. The lack of access to follow-up services for those with positive mSEPT9 screening has proven to be a challenge (particularly in light of the high test positivity rate), as has the ability to routinely remain in contact with this population, primarily due to inconsistent addresses and phone access. However, incorporation of blood-based testing in resource-poor settings may facilitate identification of individuals who would benefit most from colonoscopy and can be greatly beneficial when paired with a patient navigation program that can facilitate coordination of needed care. Many of the patients who received follow up colonoscopy after positive mSEPT9 screen were able to do so because of the assistance of patient navigation to facilitate access to financial assistance within the county safety net hospital system.

By providing mSEPT9 as an alternative method of CRC screening in MUP in South Florida, there was increased uptake of testing despite the underlying socio-economic challenges that this population faces. Lack of adequate uptake of subsequent diagnostic colonoscopy in those patients testing positive is concerning and points to the need for improved navigation coupled with the need for easier access to colonoscopy. In those who received diagnostic colonoscopy, lack of high-risk lesions is difficult to interpret until more are completed: a challenge with our transient and demographically-varied MUP. While statistically non-inferior to FIT with respect to sensitivity, specificity is ~ 80% compared to ~ 97% for FIT\(^{21,22}\). Future work will be aimed at longer follow up of patients, larger populations, and quantification of patient acceptability. In addition, an ongoing post approval study is focused on measuring repeat testing uptake over time for patients with negative test results.

One limitation of the study was that testing was provided free of charge to all participants, which would remove a cost barrier for participants. In this regard, the results may not be generalizable to the population. However, this is a typical of provision of services in a health care setting, and by way of comparison, FIT testing was also offered at no cost. On this basis, the impact on test uptake remains valid. As noted above, a second limitation was the lack of easy availability of screening colonoscopy. Recognizing this challenge, we simply reported the absence of colonoscopy screening and make no comparison claims with this method.
From a public health perspective, the increased uptake of screening is notable, though importantly, we recognize the concern that comes from screening patients who are unable to access a diagnostic colonoscopy following a positive screening test. To some degree, inability to access colonoscopy is a complication that may deter future use; however, given the variability among MUP, it’s difficult to determine ease of colonoscopy access at the time of screening. Furthermore, the lack of access to follow-up colonoscopy is a challenge in common for all non-invasive screening tests. The cost of testing represents a second public health challenge. Testing by FIT remains the least costly approach to screening, and there is and increased cost impact of blood-based testing, similar to other non-invasive methods such as stool DNA\textsuperscript{23}. However, blood-based testing has been shown to be a cost-effective approach for screening, given an observed increase in adherence to testing\textsuperscript{24}.

Modeling studies have shown that adherence to screening is a key driver in the success of screening programs\textsuperscript{10}. Our assessment of blood-based testing has clearly demonstrated that this alternative modality has the potential to improve adherence to screening in MUP, overcoming the barriers associated with the other screening methods. Combining blood-based screening with navigation for patients with positive results may be an appropriate model to improve MUP CRC screening rates.

Declarations

**Ethics approval and consent to participate**

- IRB was submitted and approved at the University of Miami: study # 20180497
- As stated in IRB: “A waiver of informed consent is appropriate, as this study meets the criteria in part 2 of c.f. 45 cfr 46.117; 21 cfr 56.109 – the research presents no more than minimal risk of harm to participants and involves no procedures for which written consent is normally required outside of the research context. All health fair patients signed informed consent for treatment at the health fairs’ registration stations. Consent is not required for this study as it is a retrospective study that aims to look back at data collected at DOCS health fairs.”

**Consent for publication**

Consent for participation in research was obtained from all participants at time of data collection, as detailed above. No individual patient’s data is included in the manuscript.

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

**Competing interests**

- The following authors declare that they have no conflict of interest to disclose:
Stephanie Ioannou
Kyle Sutherland
Daniel A. Sussman

- Author Dr. Amar R. Deshpande received a research grant from Takeda (money went to institution and grant ended May 2020); received honorarium from ABIM for being on GI test writing-committee (<$10K/year); received honorarium from GI Health Foundation for being on advisory board (<$10K/year).

**Funding**

Epigenomics Inc. donated mSEPT9 testing kits/processing, Polymedco donated FIT kits. Manuscript reviewed by Theo DeVos (see: Acknowledgements), but final decisions per authors. No other funding sources have been identified.

**Authors’ contributions**

SI was a major contributor in data collection, analysis of results, and composition of the manuscript. KS was a major contributor in data collection, analysis of results, development of supplementary materials, and composition of the manuscript. DAS was a major contributor in composition of the manuscript. ARD was a major contributor in composition of the manuscript. All authors read and approved the final manuscript.

**Acknowledgments**

We would like to thank Theo deVos of Epigenomics for his input and facilitation in donating the testing kits for the health fairs, as well as Molecular Pathology Laboratory Network, Inc for running the test samples.

**References**

1. Croke L. Colorectal Cancer Screening: ACS Updates Guideline for Adults with Average Risk. Am Fam Physician. 2019;99:129–30.

2. Frazier AL, Colditz GA, Fuchs CS, et al. Cost-effectiveness of screening for colorectal cancer in the general population. Jama. 2000;284:1954–61.

3. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med. 1993;328:1365–71.

4. Manser CN, Bachmann LM, Brunner J, et al. Colonoscopy screening markedly reduces the occurrence of colon carcinomas and carcinoma-related death: a closed cohort study. Gastrointest Endosc. 2012;76:110–7.

5. Hall IJ, Tangka FK, Sabatino SA, et al. Peer Reviewed: Patterns and Trends in Cancer Screening in the United States. Preventing chronic disease 2018;15.
6. White A, Thompson TD, White MC, et al. Cancer screening test use—United States, 2015. MMWR Morbidity mortality weekly report. 2017;66:201.

7. Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2017;112:1016.

8. Gupta S, Sussman DA, Doubeni CA, et al. Challenges and possible solutions to colorectal cancer screening for the underserved. JNCI: Journal of the National Cancer Institute 2014;106.

9. Green AR, Peters-Lewis A, Percac-Lima S, et al. Barriers to screening colonoscopy for low-income Latino and white patients in an urban community health center. J Gen Intern Med. 2008;23:834–40.

10. D’Andrea E, Ahnen DJ, Sussman DA, Najafzadeh M. Quantifying the impact of adherence to screening strategies on colorectal cancer incidence and mortality. Cancer Med. 2020;9(2):824–36. doi:10.1002/cam4.2735.

11. Joseph DA, King JB, Richards TB, et al. Peer Reviewed: Use of Colorectal Cancer Screening Tests by State. Preventing chronic disease 2018;15.

12. Jensen CD, Corley DA, Quinn VP, et al. Fecal immunochemical test program performance over 4 rounds of annual screening: a retrospective cohort study. Ann Intern Med. 2016;164:456–63.

13. Coronado GD, Petrik AF, Vollmer WM, et al. Effectiveness of a mailed colorectal cancer screening outreach program in community health clinics: the STOP CRC cluster randomized clinical trial. JAMA internal medicine. 2018;178:1174–81.

14. Hall PA, Russell SH. The pathobiology of the septin gene family. The Journal of Pathology: A Journal of the Pathological Society of Great Britain Ireland. 2004;204:489–505.

15. Song L, Li Y. Methylated Sept9 Gene is a Sensitive Biomarker for all Stages of Colorectal Cancer. Colorec Cancer. 2015;1:1–7.

16. Devos T, Tetzner R, Model F, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clinical chemistry. 2009;55:1337–46.

17. Lofton-Day C, Model F, DeVos T, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clinical chemistry. 2008;54:414–23.

18. Johnson DA, Barclay RL, Mergener K, et al. Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study. PloS one. 2014;9:e98238.

19. Patridge EF, Bardyn TP. Research electronic data capture (REDCap). Journal of the Medical Library Association: JMLA. 2018;106:142.

20. Taber JM, Aspinwall LG, Heichman KA, et al. Preferences for blood-based colon cancer screening differ by race/ethnicity. Am J Health Behav. 2014;38:351–61.

21. Potter N. et. al. Validation of a Real-Time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma. Clin Chem. 2014;60(9):1183–91.

22. Johnson D, et al. Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study. PLOS ONE. 2014;9(6):1–8. E98238.
23. Roth JA, deVos T, Ramsey SD. Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based Testing. Am Health Drug Benefits. 2019;12(5):256–62.

24. Ladabaum U, Allen J, Wandell M, Ramsey S. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies. Cancer epidemiology biomarkers prevention. 2013;22(9):1567–76.

Tables

Table 1 Septin9
| Age          |   |
|--------------|---|
| Mean – yr    | 62|
| Distribution- no. (%) |   |
| 50-59        | 199 (43) |
| 60-69        | 177 (38) |
| 70-79        | 63 (14)  |
| >80          | 21 (5)   |

| Sex– no. (%) |   |
|--------------|---|
| Male         | 179 (39) |
| Female       | 281 (61) |

| Race/Ethnicity- no. (%) |   |
|-------------------------|---|
| White (Non-Hispanic)    | 152 (33) |
| White (Hispanic)        | 147 (32) |
| Black (Afr American)    | 32 (7)   |
| Black (Caribbean/Haitian)| 101 (22)|
| Black (Hispanic)        | 6 (1)    |
| Other                   | 14 (3)   |
| Declined to Answer      | 8 (2)    |

| Primary Language Spoken in Household- no. (%) |   |
|-----------------------------------------------|---|
| English                                       | 236 (51) |
| Spanish                                       | 126 (27) |
| Haitian Creole                                | 81 (18)  |
| Other                                         | 8 (2)    |
| Declined to Answer                            | 9 (2)    |

| Health Insurance Enrollment- no. (%)          |   |
|-----------------------------------------------|---|
| Uninsured                                    | 229 (50) |
| Insured (Private, Medicaid/Medicare, or County Assistance Program) | 211 (46) |
| Declined to Answer                            | 20 (4)   |

| Seen Primary Care Physician in the Last Year- no. (%) |   |
|------------------------------------------------------|---|
| Yes          | 226 (49) |
|--------------|----------|
| No           | 215 (47) |
| Declined to Answer | 19 (4)  |
| Preferred Test– no. (%) |        |
| FIT          | 30 (7)   |
| Septin-9     | 430 (93) |
| Result, of mSEPT9 Testing– no. (% of mSEPT9) |        |
| Positive     | 88 (20)  |
| Negative     | 342 (80) |
| FIT Kits Returned– no. (% of FIT Kits Distributed) | 2 (7)   |

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Appendix1CRCScreeningQuestionnaire.docx